Search by Drug Name or NDC

    NDC 69097-0971-05 Lisinopril and Hydrochlorothiazide 25; 20 mg/1; mg/1 Details

    Lisinopril and Hydrochlorothiazide 25; 20 mg/1; mg/1

    Lisinopril and Hydrochlorothiazide is a ORAL TABLET in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Cipla USA Inc.. The primary component is HYDROCHLOROTHIAZIDE; LISINOPRIL.

    Product Information

    NDC 69097-0971
    Product ID 69097-971_2815b0ef-9835-4b49-b98d-8519e7005dc1
    Associated GPIs 36991802550320
    GCN Sequence Number 000389
    GCN Sequence Number Description lisinopril/hydrochlorothiazide TABLET 20 MG-25MG ORAL
    HIC3 A4J
    HIC3 Description ACE INHIBITOR-THIAZIDE OR THIAZIDE-LIKE DIURETIC
    GCN 88001
    HICL Sequence Number 000131
    HICL Sequence Number Description LISINOPRIL/HYDROCHLOROTHIAZIDE
    Brand/Generic Generic
    Proprietary Name Lisinopril and Hydrochlorothiazide
    Proprietary Name Suffix n/a
    Non-Proprietary Name Lisinopril and Hydrochlorothiazide Tablets
    Product Type HUMAN PRESCRIPTION DRUG
    Dosage Form TABLET
    Route ORAL
    Active Ingredient Strength 25; 20
    Active Ingredient Units mg/1; mg/1
    Substance Name HYDROCHLOROTHIAZIDE; LISINOPRIL
    Labeler Name Cipla USA Inc.
    Pharmaceutical Class Angiotensin Converting Enzyme Inhibitor [EPC], Angiotensin-converting Enzyme Inhibitors [MoA], Increased Diuresis [PE], Thiazide Diuretic [EPC], Thiazides [CS]
    DEA Schedule n/a
    Marketing Category ANDA
    Application Number ANDA204058
    Listing Certified Through 2024-12-31

    Package

    NDC 69097-0971-05 (69097097105)

    NDC Package Code 69097-971-05
    Billing NDC 69097097105
    Package 90 TABLET in 1 BOTTLE (69097-971-05)
    Marketing Start Date 2019-12-26
    NDC Exclude Flag N
    Pricing Information N/A

    Standard Product Labeling (SPL)/Prescribing Information SPL 40e6b627-63dc-4d52-aaa8-750663ad86c2 Details

    Revised: 11/2021